The U.S. and international locations worldwide have been experiencing a rising refrain of recession calls in 2022. Accordingly, the S&P 500 index is down 19% this 12 months. Alternatively, Merck (MRK -2.93%) is up 20% 12 months thus far and Pfizer (PFE -1.07%) is down solely 13%. Each outperformed the index whereas inflation stays at multi-decade highs.

As traders ponder the probability of customers tightening their purse strings, sure sectors are getting hit more durable than others. For example, the S&P Retail Choose Business Index tracks discretionary client shares within the S&P 500. The index is down 28% this 12 months. Moreover, the S&P Semiconductor Choose Business Index, which is down 30% in 2022, tracks shares supplying client electronics firms.

If inflation persists and international locations across the globe enter a recessionary interval, customers may forgo spending on retail and electronics. Nonetheless, medication is just not one thing individuals can move on to economize. Non-public or authorities insurance coverage packages typically pay prescribed drugs, often making out-of-pocket bills manageable. Here is why Pfizer and Merck may proceed to outperform in a recession.

Picture supply: Getty Pictures.

1. Pfizer

The corporate has a wide-ranging portfolio of biopharma medication that deal with breast, prostate, and pores and skin cancers. A lot of the medicines in Pfizer’s oncology portfolio are steadily rising in income and income on account of their patent safety. Gross margin for the corporate’s biopharma portfolio has elevated from  20% in 2019 to 38% in 2021.

A lot of the gross margin enchancment in 2021 got here from Pfizer’s COVID-19 vaccine. Although many traders imagine that the COVID vaccine gross sales will fall off in years to come back, it will not possible be this 12 months. Pfizer anticipates income from the vaccine will attain $32 billion in 2022. Pfizer’s COVID therapy, Paxlovid ought to add one other $22 billion.

The patent safety afforded to pharma firms like Pfizer permits them to revenue from the medication till they expire. A number of of Pfizer’s main medication are protected for the subsequent three to 5 years, giving the corporate time to earn extra income whereas the recession story performs out. Traders’ concern of Pfizer’s patent expirations may clarify the inventory’s 13% decline this 12 months.

To handle the expirations, Pfizer is plowing huge income from its COVID-19 vaccine and oral therapy into acquisitions. The corporate has already closed offers to purchase Enviornment Prescription drugs and ReViral. It has additionally agreed to purchase Biohaven Prescription drugs (BHVN 0.05%). Pfizer plans to proceed to make acquisitions with money available and future earnings. The corporate’s drug pipeline and acquisitions may present continued income and lengthen the patent safety of its total drug portfolio within the occasion of a recession. 

2. Merck

Merck’s rising drug portfolio contains therapies for cervical most cancers, acute hospital care, and Kind 2 diabetes. It additionally contains vaccines for HPV, chickenpox, and a single vaccine for measles, mumps, and rubella. Its animal well being medication have additionally offered Merck with a rising supply of revenue.

In its first-quarter earnings report, Merck introduced a 50% enhance in whole gross sales. The highest-line bounce was aided by its COVID-19 therapy. Outlier development within the therapy is just not anticipated to proceed, however worldwide income development was 18% within the first quarter after excluding it.

Administration additionally raised its full-year income steerage from $56.9 billion to $58.1 billion. As well as, it estimates full-year adjusted earnings per share to be between $7.24 and $7.36, up from $5.37 in 2021. Past 2022, analysts estimate earnings per share to develop to $8.85 in 2025. The worldwide financial outlook is just not fairly as rosy.

And there are dividends

The 2 shares might be nice candidates to outperform throughout a possible world recession, they usually additionally pay good-looking dividends. Pfizer’s dividend yield tops 3%, whereas Merck’s clocks in at just below 3%. Finally each dividend yields prime the S&P 500’s of 1.7%. Traders fearing the worst might discover shelter in these two pharma shares.